Notice to Annual General Meeting in Scandion Oncology A/S
The Board of Directors of Scandion Oncology A/S (”Scandion Oncology” or the“Company”) convenes the shareholders of Scandion Oncology to the Annual General Meeting, which will be held:
Wednesday, May 29, 2019 at 16:00 PM. Fruebjergvej 3, 2100 København
Complete notice incl. complete proposals from the Board and appendices can be found on the website of Scandion Oncology (www.scandiononcology.com).
1. Election of chairman of the meeting
2. The Board of Directors’ report on the Company’s business in the past year.
3. Presentation of the audited annual report for 2018 for approval
4. Decision regarding use of surplus or coverage of losses according to the approved annual report
5. Election of members to the Board of Directors
6. Appointment of auditor
7. Any other Business (not subject to a vote)
Items on the agenda, including complete proposals
The annual report as approved by the company's board of directors is recommended for approval by the general meeting.
The deficit for January 1, 2018 - December 31, 2018 of DKK 8,182,558 is proposed by the Board of Directors to be transferred for next year.
It is proposed that Peter Høngaard Andersen joins the board. Peter Høngaard Andersen's CV is attached as appendix 1. It is proposed to re-elect the existing board (Jørgen Vilhelm Løvenørn Bardenfleth, Carl Arne Krister Borrebaeck, Thomas Feldthus and Christian Vinding Thomsen).
It is proposed to re-elect the current auditor (Deloitte).
No suggestions received.
Registration date and shareholders’ voting rights
The registration date is May 22, 2019. Only persons who are shareholders on this date have the right to participate in and vote at the general meeting.
Admission Card & Proxy
In order to obtain physical access to the general meeting and thereby be able to participate in and vote at the general meeting, a shareholder must have requested an admission card no later than three days before the general meeting, cf. section 7.5 of the articles of association. Please contact Carit Jacques Andersen, e-mail email@example.com. The request must be received no later than Friday, May 24, 2019, at 23.59. A shareholder also has the option of requesting an admission card for a proxy that gives a physical meeting on behalf of the shareholder. The request must be made according to the above guidelines. If necessary, the shareholder must complete and sign the proxy and postal voting form that is available on the company's website www.scandiononcology.com. The proxy must bring the admission card and the original form at the general meeting.
Questions from shareholders
Shareholders have the right to ask questions on the agenda on the issues to be discussed at the general meeting. The questions can be asked in writing before the general meeting or at the general meeting. The answer will - with the limitations that follow from the legislation - if possible, take place at the general meeting or be made available to the shareholders no later than 2 weeks after the general meeting.
All material mentioned in this notice can be obtained from Carit Jacques Andersen, e-mail firstname.lastname@example.org. The material will only be forwarded per e-mail, hence e-mail address must be specified.
Appendix 1: CV for Peter Høngaard Andersen.
Appendix 2: Authorized voting form.
With regards to collection and processing of personal data for the Annual General Meeting, these are handled, stored and deleted in accordance with the General Data Protection Regulation (GDPR).
The Board of Directors of
SCANDION ONCOLOGY A/S
For additional information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology was listed on Spotlight, Sweden in November 2018.